Meanwhile, 13.8% of NSCLC patients at the advanced stage receiving PD-1/PD-L1 inhibitors treatment are reported to sustain accelerated tumor growth during immunotherapy, which is defined as the hyperprogressive disease (HPD) [3]. Here, PDCD1 is linked to neoplasm.